9 Meters Biopharma to Present at the H.C. Wainwright Global Investment Conference and the LifeSci Partners Immunology & Inflammation Symposium
9 Meters Biopharma, Inc. (NASDAQ:NMTR) announced that President & CEO John Temperato will present at two upcoming events: the LifeSci Partners Immunology & Inflammation Symposium on May 10, 2022, and the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The presentations will focus on the company’s pipeline, including vurolenatide for short bowel syndrome and larazotide for celiac disease. Data from both studies is anticipated in the coming months, highlighting the company's commitment to rare digestive diseases.
- None.
- None.
RALEIGH, NC / ACCESSWIRE / May 5, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that John Temperato, President & Chief Executive Officer of 9 Meters, will present at the LifeSci Partners Immunology & Inflammation Symposium on May 10, 2022, and the H.C. Wainwright Global Investment Conference to be held on May 23-26, 2022.
LifeSci Capital Immunology & Inflammation Symposium
Presentation Date: Tuesday, May 10, 2022
Time: 10:00 AM EDT
Webcast link
H.C. Wainwright Global Investment Conference
Presentation: Available for viewing beginning Tuesday, May 24 at 7:00 AM EDT
Webcast link
The presentations will also be available in the events section of the 9 Meters website.
The presentation will highlight the Company's advanced pipeline and upcoming clinical milestones for vurolenatide, its long-acting GLP-1 agonist for short bowel syndrome, currently in a Phase 2 clinical study with data anticipated in the second quarter of 2022, and larazotide, its Phase 3 tight junction regulator for celiac disease, with an interim analysis anticipated in early June 2022.
About 9 Meters Biopharma
9 Meters Biopharma, Inc. is a clinical-stage company pioneering novel treatments for people with rare digestive diseases, GI conditions with unmet needs, and debilitating disorders in which the biology of the gut is a contributing factor. The Company is advancing vurolenatide, a proprietary Phase 2 long-acting GLP-1 agonist, for short bowel syndrome (SBS); larazotide, a Phase 3 tight junction regulator in non-responsive celiac disease; and several near clinical-stage assets.
For more information please visit www.9meters.com or follow 9 Meters on Twitter and LinkedIn.
Forward-Looking Statements
This press release includes forward-looking statements based upon 9 Meters' current expectations. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, anticipated milestones, and any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation: uncertainties associated with the clinical development and regulatory approval of product candidates; reliance on collaborators; reliance on research and development partners; uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom; risks related to the failure to realize any value from product candidates and preclinical programs being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; intellectual property risks; the impact of COVID-19 on our operations, enrollment in and timing of clinical trials; risks related to the inability of 9 Meters to obtain sufficient additional capital to continue to advance these product candidates and its preclinical programs, including in light of current stock market conditions; risk of delisting from Nasdaq; risks related to cybersecurity and data privacy; and risks associated with acquiring and developing additional compounds. These and other risks and uncertainties are more fully described in periodic filings with the SEC, including the factors described in the section entitled "Risk Factors" in 9 Meters' Annual Report on Form 10-K for the year ended December 31, 2021, and in other filings that 9 Meters has made and future filings 9 Meters will make with the SEC. You should not place undue reliance on these forward-looking statements, which are made only as of the date hereof or as of the dates indicated in the forward-looking statements. 9 Meters expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
Corporate Contact
Al Medwar
SVP, Investor Relations & Corporate Communications
9 Meters Biopharma, Inc.
investor-relations@9meters.com
Media Contact
Veronica Eames
LifeSci Communications, LLC
veames@lifescicomms.com
203-942-4626
SOURCE: 9 Meters Biopharma, Inc.
View source version on accesswire.com:
https://www.accesswire.com/700147/9-Meters-Biopharma-to-Present-at-the-HC-Wainwright-Global-Investment-Conference-and-the-LifeSci-Partners-Immunology-Inflammation-Symposium
FAQ
What presentations is 9 Meters Biopharma scheduled for in May 2022?
What key products will be highlighted by 9 Meters Biopharma in its presentations?
When is the data for vurolenatide expected to be released?
What is the significance of the H.C. Wainwright Global Investment Conference for NMTR?
How can I access the presentations of 9 Meters Biopharma?
